![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
USAGE OF DRUGS IN THE TREATMENT OF CHRONIC KIDNEY DISEASE WITH MINERAL BONE DISORDER
Vedavathi Sai G., Kavyashree M. P.*, Susmita Kanaujiya and Dr. Mahadevamma Lingaiah
ABSTRACT
CKD-MBD is a systemic disorder of mineral and bone metabolism brought on by CKD and characterised by aberrant calcium, phosphorus, PTH, or vitamin D metabolism. This study aimed to identify the drug usage patterns in the management of CKD-MBD. This study was a prospective study performed on 182 patients, in the nephrology department, Sagar Hospital. It was assessed and evaluated by a suitable statistical tool. In this study, Men had a larger prevalence (67%) than women(33%), and more patients were observed in the 51-70 age range. Hypertension, DM (90%) discovered in males (30.8%) and females (18.7%) had the highest prevalence rate of comorbidity. Calcium, phosphorus, and parathyroid hormone are the criteria that prove MBD because CKD-MBD is likely to cause them to be abnormal. The prominent non- pharmacotherapy treatment was a renal diet with 1500kcal and 50g of protein. Furosemide (39%) was Keywords: CKD-MBD, parathyroid hormone, vitamin supplements, cholecalciferol calcium. [Download Article] [Download Certifiate] |